Walleye Capital
KROS icon

Walleye Capital’s Keros Therapeutics KROS Stock Holding History

Walleye Capital’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-150,503
Closed -$1.53M – 4798
2025
Q1 		$1.53M Sell
150,503
-47,163
-24% -$548K 0.01% 1645
2024
Q4 		$3.13M Buy
+197,666
New +$10.3M 0.01% 1397
2023
Q2 		– Sell
-67,636
Closed -$2.89M – 4606
2023
Q1 		$2.89M Buy
67,636
+58,833
+668% +$2.97M 0.04% 519
2022
Q4 		$423K Sell
8,803
-8,655
-50% -$404K 0.01% 1558
2022
Q3 		$657K Sell
17,458
-22,642
-56% -$785K 0.01% 1261
2022
Q2 		$1.11M Buy
40,100
+11,054
+38% +$485K 0.03% 593
2022
Q1 		$1.58M Buy
+29,046
New +$1.49M 0.04% 441

Other funds holding KROS

ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
WSL
Western Standard LLC Los Angeles, California $190M AUM 40.88% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Walleye Capital's KROS Position: Q2 2025 in Review

Walleye Capital sold out of Keros Therapeutics (KROS) in Q2 2025, closing a stake of 150,503 shares — an estimated $1.53M sold.

Walleye Capital first reported a position in KROS in Q1 2022 and held it in 7 quarters. The position peaked at $3.13M in Q4 2024. 139 funds tracked by Wall St. Rank hold KROS as of Q2 2025.

  • Walleye Capital reported no remaining Keros Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Walleye Capital sold 150,503 Keros Therapeutics shares in Q2 2025, an estimated $1.53M.
  • Walleye Capital first reported a position in Keros Therapeutics in Q1 2022 and held it in 7 quarters.
  • Walleye Capital's Keros Therapeutics position peaked at $3.13M in Q4 2024.
  • 139 funds tracked by Wall St. Rank held Keros Therapeutics as of Q2 2025.

Based on Walleye Capital's 13F filing for Q2 2025, filed 13 Aug 2025.